Clinical trial · Observational
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
NCT05692596CI-TRIAL-00107014active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.
Conditions
Conditions (13)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ataxia Telangiectasia | — | UNRESOLVED | — |
| BRCA Mutation | — | UNRESOLVED | — |
| Chronic Pancreatitis | — | UNRESOLVED | — |
| Familial Atypical Multiple Mole-Melanoma | — | UNRESOLVED | — |
| FAP | — | UNRESOLVED | — |
| Fatty Pancreas | — | UNRESOLVED | — |
| Genetic Pancreatic Cancer | — | UNRESOLVED | — |
| Genetic Pancreatitis | — | UNRESOLVED | — |
| Lynch Syndrome | — | UNRESOLVED | — |
| PALB2 Gene Mutation | — | UNRESOLVED | — |
| Pancreatic Cyst | — | UNRESOLVED | — |
| Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All participants
- description
- Participants include patients scheduled to see the clinical team in the Pancreas Interception Center (PIC) which will be housed in the Moffitt GI Clinic.
- interventionNames
- Other: Data collection
Primary outcomes (1)
- measure
- Database creation
- timeFrame
- 24 months
- description
- A centralized, real-time, queryable and secure database will be developed that will integrate data on Moffitt patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), pancreatic cystic lesions (benign, pre-cancerous and malignant), or an inherited PDAC susceptibility.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC) * Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC. * Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.
References
Publications (0)
Data not yet available
No reference posted for this study.